Search research articles
Contact Us
Filters
Showing results (71-80 of 109) with videos related to
Page
of 11
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
June 5, 2012
A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia
Khanh Vu, Naifa Busaidy, Maria E Cabanillas, et al.
Blood
|
May 6, 2003
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome
Hesham M Amin, Iman Jilani, Elihu H Estey, et al.
The New England Journal of Medicine
|
September 17, 2010
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
Srdan Verstovsek, Hagop Kantarjian, Ruben A Mesa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 31, 2004
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome
Razelle Kurzrock, Maher Albitar, Jorge E Cortes, et al.
British Journal of Haematology
|
July 29, 2014
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia
Christopher B Benton, Deborah A Thomas, Hui Yang, et al.
The Journal of Experimental Medicine
|
May 25, 2011
Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia
Lynn M Heltemes-Harris, Mark J L Willette, Laura B Ramsey, et al.
Blood
|
June 22, 2012
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
Srdan Verstovsek, Hagop M Kantarjian, Zeev Estrov, et al.
Blood
|
June 21, 2008
The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms
Constantine S Tam, Roberto M Nussenzveig, Uday Popat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2003
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias
Francis J Giles, Stefan Faderl, Deborah A Thomas, et al.
Blood
|
August 27, 2005
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia
Stefan Faderl, Kim-Anh Do, Marcella M Johnson, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 109) with videos related to
Sort By:
Page
of 11
Clinical Lymphoma, Myeloma & Leukemia
|
June 5, 2012
A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia
Khanh Vu, Naifa Busaidy, Maria E Cabanillas, et al.
Blood
|
May 6, 2003
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome
Hesham M Amin, Iman Jilani, Elihu H Estey, et al.
The New England Journal of Medicine
|
September 17, 2010
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
Srdan Verstovsek, Hagop Kantarjian, Ruben A Mesa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 31, 2004
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome
Razelle Kurzrock, Maher Albitar, Jorge E Cortes, et al.
British Journal of Haematology
|
July 29, 2014
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia
Christopher B Benton, Deborah A Thomas, Hui Yang, et al.
The Journal of Experimental Medicine
|
May 25, 2011
Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia
Lynn M Heltemes-Harris, Mark J L Willette, Laura B Ramsey, et al.
Blood
|
June 22, 2012
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
Srdan Verstovsek, Hagop M Kantarjian, Zeev Estrov, et al.
Blood
|
June 21, 2008
The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms
Constantine S Tam, Roberto M Nussenzveig, Uday Popat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2003
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias
Francis J Giles, Stefan Faderl, Deborah A Thomas, et al.
Blood
|
August 27, 2005
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia
Stefan Faderl, Kim-Anh Do, Marcella M Johnson, et al.
Page
of 11